Abstract
Purpose.
Advanced cutaneous T-cell lymphoma (CTCL) is a hard-to-treat condition. Complete response is rare even with polychemotherapy. The use of liposomal formulation anti-cancer drugs can improve the efficacy and the risk-benefit ratio. Liposomal doxorubicin was shown to be effective as a second-line treatment in CTCL. There is no data available on another classical anthracycline, daunorubicin, when given in liposomal formulation as a monotherapy.
Methods.
Monotherapy with liposomal-encapsulated daunorubicin (DNX) was given as a monotherapy once a month at 20 mg/m2 three times to achieve a clinical response. In the case of limited response the drug was given once every 3 weeks and a dose increase was performed. Three patients were treated.
Results.
A complete response was achieved in one patient (dosage 20 mg/m2 once per month). Two other patients achieved a partial response. The final outcome was disease-free survival of more than 10 months in the patient with a complete response and survival of >8 months and 6 months in those with a partial response. Adverse effects were grade 4 anemia in one patient, lymphopenia grade 2 with grade 1 anemia, and grade 1 lymphopenia in the other patients.
Conclusion.
This is the first report on DNX monotherapy in CTCL. In a small group of three patients a response rate of 100% was achieved with one complete response. DNX seems to be another option in advanced cases of CTCL.
This is a preview of subscription content, log in via an institution to check access.
References
Bellott R, Auvrignon A, Leblanc T, Perel Y, Gandemer V, Betrand Y, Mechinaud F, Bellenger P, Vernois J, Leverger G, Baruchel A, Robert J (2001) Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 47:15–21
Boulland ML, Wechlser J, Bagot M, Pulford K, Kanavaros P, Gaular P (2000) Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 36:136–144
Cabanes A, Tzemach D, Goren D, Horowitz AT, Gabizon A (1998) Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model. Clin Cancer Res 4:499–505
Cabriales S, Bresnahan J, Testa D, Espina BM, Scadden DT, Ross M, Gill PS (1998) Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases. Oncol Nurs Forum 25:67–70
Cortes J, O'Brien S, Estey E, Giles F, Keating M, Kantarjaan H (1999) Phase I study of liposomal daunorubicin in patients with acute leukaemia. Invest New Drug 17:81–87
Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukaemia. Cancer 92:7–14
Flinn IW, Goodman SN, Post L, Jamison J, Miller CB, Gore S, Diehl L, with CVP (COP-X) in advanced NHL. Ann Oncol 11:691–695
Harrington KJ (2001) Liposomal cancer chemotherapy: current clinical applications and future prospects. Expert Opin Investig Drugs 10:1045–1061
Hui YF, Cortes JE (2000) Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 20:1221–1223
Lorincz AL (1996) Cutaneous T-cell lymphoma (mycosis fungoides). Lancet 347:871–876
McBride NC, Cavenagh JD, Ward MC, Grant I, Schey S, Gray A, Hughes A, Mills MJ, Cervi P, Newland AC, Kelsey SM (2001) Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkins lymphoma. Leuk Lymphoma 42:89–98
Muggia FM (2001) Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 3:156–162
Richardson DS, Kelsey SM, Johnson SA, Tighe M, Cavenagh JD, Newland AC (1997) Early evaluation of liposomal daunorubicin (DaunoXome, Nextar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 15:247–253
Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M (2001) Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol Oncol 82:323–328
Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, Espina BM, Rraynor A, Letzer J, Justice GR, McDonald D, Roberts L, Boswell W, Nathwani B, Levine AM (2001) Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 12:457–462
Vermeer MH, Tensen CP, van der Stoop PM, van Ostveen HW, Lind M, Scheper RJ, Willemze R (2001) Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. Arch Dermatol 137:901–905
Wollina U, Graefe T, Karte K (2000) Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin. J Am Acad Dermatol 42:40–46
Wollina U, Graefe T, Kaatz M (2001) Pegylated doxorubicin for primary cutaneous T-cell lymphoma: a report on 10 patients with follow-up. J Cancer Res Clin Oncol 127:128–134
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wollina, U., Hohaus, K., Schönlebe, J. et al. Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma. J Cancer Res Clin Oncol 129, 65–69 (2003). https://doi.org/10.1007/s00432-002-0403-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-002-0403-9